Adipotide
A synthetic peptidomimetic that starves white fat tissue by triggering apoptosis in the blood vessels that feed it.
Adipotide is a vascular-targeting peptidomimetic that binds prohibitin, a marker overexpressed on the vasculature of white adipose tissue, and delivers a pro-apoptotic payload that kills the blood vessels supplying fat. By cutting off the fat tissue's blood supply rather than suppressing appetite, it produced substantial fat and body-weight loss in rodents and obese monkeys. Human development for obesity was halted after a Phase 1 trial surfaced renal toxicity signals, and the compound is not approved for any medical indication.
Class
Synthetic vascular-targeting peptidomimetic (homing peptide + pro-apoptotic peptide conjugate)
Routes
Subcutaneous (research use)
Category
Weight Loss & Metabolic
Researched benefits
What it's studied for
Substantial fat-mass reduction
In preclinical rodent and rhesus monkey studies, Adipotide produced large reductions in body fat by physically destroying adipose tissue rather than modulating appetite. Obese monkeys lost up to roughly 11% of body weight over about 4 weeks.
Vascular-targeted rather than appetite-based
Unlike GLP-1-class agents that reduce caloric intake, Adipotide induces regression of fat tissue via vascular starvation, a fundamentally different mechanism that acts on the fat depot directly.
Proof-of-mechanism in humans
A Phase 1 trial in men with prostate cancer demonstrated that the vascular-targeting approach engages its target in humans, establishing proof-of-mechanism even though obesity efficacy was never clinically confirmed.
Reference compound for obesity research
As one of the earliest vascular-targeting approaches to obesity, Adipotide remains a scientific reference point for studying adipose-tissue vasculature as a therapeutic target.
Mechanism
How it works
Adipotide is a peptidomimetic built from two joined parts: a homing peptide that binds prohibitin, a protein marker overexpressed on the endothelial cells lining the blood vessels of white adipose tissue, and a pro-apoptotic peptide, (KLAKLAK)2, that disrupts mitochondria and triggers cell death once it is internalized.
By selectively binding the vasculature of fat tissue, Adipotide concentrates its cytotoxic payload in the blood vessels that supply white adipose depots. The (KLAKLAK)2 moiety then induces mitochondrial disruption and apoptosis in that targeted endothelium, killing the fat-supplying blood vessels.
With their blood supply destroyed, adipocytes undergo regression through vascular starvation. This is why Adipotide reduces fat mass without acting on appetite or systemic metabolism the way GLP-1-class peptides do — it physically eliminates the fat tissue's support system rather than reducing caloric intake.
The same targeting that concentrates the peptide in adipose vasculature also allowed off-target accumulation in kidney tissue, which is believed to underlie the renal toxicity (proteinuria, elevated creatinine) observed in the Phase 1 human trial and which ultimately halted development for obesity.
Evidence
Research & clinical studies (3)
Vascular-targeted proapoptotic peptide (Adipotide) Phase 1 trial in men with prostate cancer
Barnhart et al. reported a first-in-human Phase 1 study demonstrating proof-of-mechanism for the vascular-targeting approach while surfacing renal toxicity signals attributed to off-target peptide accumulation in kidney tissue.
Adipotide-induced fat-mass and body-weight reduction in obese non-human primates
Obese rhesus monkeys treated with Adipotide showed substantial fat-mass loss and up to roughly 11% body-weight reduction over about 4 weeks.
Adipotide fat-mass reduction in rodent obesity models
Rodent studies demonstrated substantial reductions in fat mass and body weight via vascular-targeted adipocyte apoptosis, with transient renal effects observed.
Safety
Side effects & considerations
Commonly reported effects
Contraindications & cautions
- Any existing or suspected kidney impairment
- Human use of any kind (not approved for human consumption)
The Phase 1 human trial surfaced renal toxicity signals attributed to off-target peptide accumulation in kidney tissue, and this finding halted development for non-life-threatening indications including obesity. Animal studies showed transient renal effects, but the human renal signal was the development-stopping factor.
FAQ
Adipotide — common questions
Why was Adipotide's obesity development halted?
Its Phase 1 human trial surfaced renal toxicity signals (proteinuria, elevated creatinine) attributed to off-target peptide accumulation in kidney tissue, giving it an unfavorable risk-benefit profile for a non-life-threatening indication like obesity.
Is Adipotide effective for fat loss?
Preclinical rodent and rhesus monkey studies showed substantial fat-mass reduction, and the Phase 1 human trial demonstrated proof-of-mechanism in prostate cancer patients, but the renal toxicity signal halted obesity-specific human trials before efficacy was clinically established for that indication.
How is Adipotide different from GLP-1 weight-loss peptides?
Adipotide physically kills fat tissue by destroying its blood supply (vascular-targeted apoptosis), whereas GLP-1 agonists like semaglutide and tirzepatide reduce caloric intake through appetite suppression and metabolic modulation. The mechanisms are not therapeutically comparable, and unlike Adipotide, GLP-1 compounds have reached FDA approval.
Is Adipotide legal to purchase?
It is legal to purchase as a research chemical for laboratory use in most jurisdictions, but it is not approved for human consumption anywhere and carries documented renal toxicity signals from human trials.
What is Adipotide's regulatory status?
Adipotide is not approved for any medical indication anywhere in the world. Its clinical development for obesity was discontinued for safety reasons, and it remains available only as research-use-only material.
Are there safer alternatives for fat-loss research?
FDA-approved weight-management options such as semaglutide and tirzepatide have established safety profiles, and retatrutide is in late-stage development. These are not direct mechanism analogs to Adipotide but are evidence-based options for the weight-loss question.
